olmesartan medoxomil has been researched along with Focal Segmental Glomerulosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quiroz, Y; RodrÃguez-Iturbe, B; Sato, T; Vaziri, ND | 1 |
| Inoue, H; Takeuchi, M; Yamagishi, S | 1 |
2 other study(ies) available for olmesartan medoxomil and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cholesterol, VLDL; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Male; Olmesartan Medoxomil; Pravastatin; Proteinuria; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Renal Insufficiency; Tetrazoles; Triglycerides | 2004 |
Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats.
Topics: Acetylglucosamine; Angiotensin II Type 2 Receptor Blockers; Animals; Body Weight; Glomerulosclerosis, Focal Segmental; Glycation End Products, Advanced; Imidazoles; Kidney Diseases; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; Tetrazoles; Tissue Fixation | 2005 |